Biodexa Pharmaceuticals Plc
BDRX
$1.55
-$0.01-0.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 51.60K | 104.10K | 290.60K | 471.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 51.60K | 104.10K | 290.60K | 471.50K |
| Cost of Revenue | 6.96M | 6.01M | 5.05M | 5.07M | 5.05M |
| Gross Profit | -6.96M | -5.96M | -4.94M | -4.78M | -4.58M |
| SG&A Expenses | 4.84M | 4.18M | 3.50M | 3.65M | 3.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.10K | -28.90K | -17.60K | -17.60K | -17.60K |
| Total Operating Expenses | 11.77M | 10.16M | 8.53M | 8.71M | 8.79M |
| Operating Income | -11.77M | -10.11M | -8.43M | -8.42M | -8.32M |
| Income Before Tax | -7.63M | -8.25M | -8.89M | -9.14M | -9.31M |
| Income Tax Expenses | -319.40K | -312.70K | -306.10K | -407.50K | -503.10K |
| Earnings from Continuing Operations | -7.31 | -7.94 | -8.59 | -8.73 | -8.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.31M | -7.94M | -8.59M | -8.73M | -8.80M |
| EBIT | -11.77M | -10.11M | -8.43M | -8.42M | -8.32M |
| EBITDA | -11.62M | -9.95M | -8.25M | -8.24M | -8.14M |
| EPS Basic | -174.71K | -560.81K | -954.42K | -890.83K | -826.90K |
| Normalized Basic EPS | -11.37 | -26.74 | -42.41 | -38.28 | -34.14 |
| EPS Diluted | -174.71K | -560.81K | -954.42K | -890.83K | -826.90K |
| Normalized Diluted EPS | -11.37 | -26.74 | -42.41 | -38.28 | -34.14 |
| Average Basic Shares Outstanding | 1.98M | 1.37M | 762.80K | 434.70K | 106.60K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |